Page 5 - Systemic Therapy News Today

Find current treatment regimens for small cell lung cancer, including options such as pemetrexed, pemetrexed + cisplatin, and vinorelbine.

Press release content from PR Newswire. The AP news staff was not involved in its creation.

- New appointments as part of the Companys strategic development plans to accelerate transformation towards commercialization - Dr. Andrew Zhu, an...

/PRNewswire/ -- Thompson Child & Family Focus (Thompson) has been selected as a direct service provider of Multi-Systemic Therapy (MST) services for two...

CHARLOTTE, N.C., Oct. 22, 2021 /PRNewswire/ -- Thompson Child & Family Focus (Thompson) has been selected as a direct service provider of Multi-Systemic Therapy (MST) services for two regions in

Zum Start des Christopher Street Days in Bremen wird eine große Regenbogenflagge auf den Bahnhofsvorplatz gemalt. Viele Menschen sind gekommen, um ein ...

Long-term data from PACIFIC Phase III trial at ASCO showed 33% of patients remained progression-free at five years Longest-ever survival reported in a Phase III immunotherapy trial in this setting ...

Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting News provided by Share this article Share this article INDIANAPOLIS, May 19, 2021 /PRNewswire/ -- New data from across Eli Lilly and Companys (NYSE: LLY) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 4-8, 2021. The data include new analyses of Verzenio ® (abemaciclib) from the Phase 3 monarchE trial in patients ...

Kite, a unit of Gilead Sciences, announced that the US Food and Drug Administration (FDA) has approved its Yescarta T cell immunotherapy. The therapy is a first-of-its-kind treatment for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The Gilead (GILD) company said that the US regulator’s decision was based on ZUMA-5, a single-arm, open-label study, that demonstrated 91% of patients with relapsed or refractory FL (n=81) resp...

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation, and Degeneration 2021 conference on February 13, 2021 Clearside Biomedical, Inc. , a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision fo...